AstraZeneca PLC Filing of Form 20-F with SEC
February 21 2024 - 1:00AM
RNS Regulatory News
RNS Number : 7687D
AstraZeneca PLC
21 February 2024
21 February 2024 07:00
GMT
Filing of Annual Report on
Form 20-F with the US Securities and Exchange
Commission
AstraZeneca PLC (the
Company) announced today that, on 20 February 2024, it filed
its 2023 Annual Report on Form 20-F with the US Securities and
Exchange Commission (SEC). The document is available for viewing on
the SEC website at www.sec.gov and also on the
Company's website at www.astrazeneca.com.
The Company will send any holder of the Company's securities, upon
request, a hard copy of the Company's complete audited financial
statements free of charge. Requests may be made by writing to the
Company Secretary, AstraZeneca PLC, 1 Francis Crick
Avenue, Cambridge Biomedical Campus, Cambridge, CB2
0AA, UK.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
MSCSELSUSELSESE
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024